TY - JOUR
T1 - A systematic review of clinical practice guidelines for the diagnosis and management of bronchiolitis
AU - Kirolos, Amir
AU - Manti, Sara
AU - Blacow, Rachel
AU - Tse, Gabriel
AU - Wilson, Thomas
AU - Lister, Martin
AU - Cunningham, Steve
AU - Campbell, Alasdair
AU - Nair, Harish
AU - Reeves, Rachel M.
AU - Fernandes, Ricardo M.
AU - Campbell, Harry
AU - Campbell, Harry
AU - Nair, Harish
AU - Reeves, Rachel M.
AU - Douglas, Anne
AU - Cunningham, Steve
AU - Meijer, Adam
AU - Fischer, Thea Kølsen
AU - Heikkinen, Terho
AU - Giaquinto, Carlo
AU - Knirsch, Charles
AU - Stoszek, Sonia
AU - Leach, Amanda
AU - Demont, Clarisse
AU - Gallichan, Scott
AU - Aerssens, Jeroen
AU - Beutels, Philippe
AU - Bont, Louis
AU - Pollard, Andrew
AU - Openshaw, Peter
AU - Hackett, Judy
AU - Rosen, Brian
AU - Molero, Eva
N1 - Funding Information:
Potential conflicts of interest. H. N. reports receiving grants and personal fees from the Bill and Melinda Gates Foundation during the conduct of the study and receiving grants and personal fees from the World Health Organization and Sanofi and grants from the Innovative Medicines Initiative (Horizon 2020) and the National Institute of Health Research outside the submitted work. S. C. is chair of the NICE panel, which wrote one of the guidelines assessed in this manuscript but was not involved in the quality assessment of guidelines, and reports receiving fees from Janssen, Ablynx, ReViral, and Pulmocide outside of the submitted work. H. C. reports receiving grants and personal fees from the World Health Organization, the Bill and Melinda Gates Foundations, and Sanofi during the conduct of the study. R. M. F. is an author in one of the included guidelines (Portugal). All other authors: No reported conflicts.
Funding Information:
Financial support. This work was supported by the Innovative Medicines Initiative 2 Joint Undertaking (grant 116019 to RESCEU), which is supported by the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations.
Publisher Copyright:
© The Author(s) 2019.
PY - 2021
Y1 - 2021
N2 - Background. Bronchiolitis is the leading cause of hospital admission for respiratory disease among infants aged <1 year. Clinical practice guidelines can benefit patients by reducing the performance of unnecessary tests, hospital admissions, and treatment with lack of a supportive evidence base. This review aimed to identify current clinical practice guidelines worldwide, appraise their methodological quality, and discuss variability across guidelines for the diagnosis and management of bronchiolitis. Methods. A systematic literature review of electronic databases EMBASE, Global Health, and Medline was performed. Manual searches of the gray literature, national pediatric society websites, and guideline-focused databases were performed, and select international experts were contacted to identify additional guidelines. The Appraisal of Guidelines for Research and Evaluation assessment tool was used by 2 independent reviewers to appraise each guideline. Results. Thirty-two clinical practice guidelines met the selection criteria. Quality assessment revealed significant shortcomings in a number of guidelines, including lack of systematic processes in formulating guidelines, failure to state conflicts of interest, and lack of consultation with families of affected children. There was widespread agreement about a number of aspects, such as avoidance of the use of unnecessary diagnostic tests, risk factors for severe disease, indicators for hospital admission, discharge criteria, and nosocomial infection control. However, there was variability, even within areas of consensus, over specific recommendations, such as variable thresholds for oxygen therapy. Guidelines showed significant variability in recommendations for the pharmacological management of bronchiolitis, with conflicting recommendations over whether use of nebulized epinephrine, hypertonic saline, or bronchodilators should be routinely trialled. Conclusions. Future guidelines should aim to be compliant with international standards for clinical guidelines to improve their quality and clarity and to promote their adoption into practice. Variable recommendations between guidelines may reflect the evolving evidence base for bronchiolitis management, and platforms should be created to understand this variability and promote evidence-based recommendations.
AB - Background. Bronchiolitis is the leading cause of hospital admission for respiratory disease among infants aged <1 year. Clinical practice guidelines can benefit patients by reducing the performance of unnecessary tests, hospital admissions, and treatment with lack of a supportive evidence base. This review aimed to identify current clinical practice guidelines worldwide, appraise their methodological quality, and discuss variability across guidelines for the diagnosis and management of bronchiolitis. Methods. A systematic literature review of electronic databases EMBASE, Global Health, and Medline was performed. Manual searches of the gray literature, national pediatric society websites, and guideline-focused databases were performed, and select international experts were contacted to identify additional guidelines. The Appraisal of Guidelines for Research and Evaluation assessment tool was used by 2 independent reviewers to appraise each guideline. Results. Thirty-two clinical practice guidelines met the selection criteria. Quality assessment revealed significant shortcomings in a number of guidelines, including lack of systematic processes in formulating guidelines, failure to state conflicts of interest, and lack of consultation with families of affected children. There was widespread agreement about a number of aspects, such as avoidance of the use of unnecessary diagnostic tests, risk factors for severe disease, indicators for hospital admission, discharge criteria, and nosocomial infection control. However, there was variability, even within areas of consensus, over specific recommendations, such as variable thresholds for oxygen therapy. Guidelines showed significant variability in recommendations for the pharmacological management of bronchiolitis, with conflicting recommendations over whether use of nebulized epinephrine, hypertonic saline, or bronchodilators should be routinely trialled. Conclusions. Future guidelines should aim to be compliant with international standards for clinical guidelines to improve their quality and clarity and to promote their adoption into practice. Variable recommendations between guidelines may reflect the evolving evidence base for bronchiolitis management, and platforms should be created to understand this variability and promote evidence-based recommendations.
KW - Bronchiolitis
KW - Diagnosis
KW - Guidelines
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85085594246&partnerID=8YFLogxK
U2 - 10.1093/INFDIS/JIZ240
DO - 10.1093/INFDIS/JIZ240
M3 - Review article
C2 - 31541233
AN - SCOPUS:85085594246
SN - 0022-1899
VL - 222
SP - S672-S679
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -